Literature DB >> 23970915

Outside the Black Box: Re-assessing Pediatric Antidepressant Prescription.

Jacqueline A Sparks1, Barry L Duncan.   

Abstract

OBJECTIVE: The purpose of this review is to assess whether evidence supports a favorable risk/benefit profile for pediatric antidepressant use and reconsideration of the black box.
METHOD: The review examines studies post-black box purporting to show declines in pediatric antidepressant use and rising youth suicide, summarizes evidence for efficacy and safety of pediatric antidepressants, and discusses irregularities in recent meta-analyses of fluoxetine for youth.
RESULTS: Pediatric antidepressant prescription did not significantly decline post-black box and youth suicide has risen only in recent years. Recent meta-analyses fail to undermine evidence that antidepressants are associated with increased risk of suicidality in youth.
CONCLUSIONS: First line prescription of antidepressants for youth is not advisable. The black box and international warnings on pediatric use of antidepressants are warranted. Wider availability of psychosocial options for depressed youth is recommended.

Entities:  

Keywords:  SSRIs; adolescents; antidepressants; black box; children; suicide

Year:  2013        PMID: 23970915      PMCID: PMC3749900     

Source DB:  PubMed          Journal:  J Can Acad Child Adolesc Psychiatry        ISSN: 1719-8429


  36 in total

1.  Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008.

Authors:  Qiuping Gu; Charles F Dillon; Vicki L Burt
Journal:  NCHS Data Brief       Date:  2010-09

2.  Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: a meta-analysis.

Authors:  Andrew D Mosholder; Mary Willy
Journal:  J Child Adolesc Psychopharmacol       Date:  2006 Feb-Apr       Impact factor: 2.576

3.  Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes.

Authors:  Graham J Emslie; Taryn Mayes; Giovanna Porta; Benedetto Vitiello; Greg Clarke; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Anthony Spirito; Boris Birmaher; Neal Ryan; Betsy Kennard; Lynn DeBar; James McCracken; Michael Strober; Matthew Onorato; Jamie Zelazny; Marty Keller; Satish Iyengar; David Brent
Journal:  Am J Psychiatry       Date:  2010-05-17       Impact factor: 18.112

4.  Rising prevalence of antidepressants among US youths.

Authors:  Julie Magno Zito; Daniel J Safer; Susan DosReis; James F Gardner; Karen Soeken; Myde Boles; Frances Lynch
Journal:  Pediatrics       Date:  2002-05       Impact factor: 7.124

5.  Trends of outpatient prescription drug utilization in US children, 2002-2010.

Authors:  Grace Chai; Laura Governale; Ann W McMahon; James Phillip Trinidad; Judy Staffa; Dianne Murphy
Journal:  Pediatrics       Date:  2012-06-18       Impact factor: 7.124

6.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

Authors:  John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

Review 7.  An update on antidepressant use and suicidality in pediatric depression.

Authors:  Clara Adegbite-Adeniyi; Brittany Gron; Brieana M Rowles; Christine A Demeter; Robert L Findling
Journal:  Expert Opin Pharmacother       Date:  2012-10       Impact factor: 3.889

Review 8.  Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management.

Authors:  Amy H Cheung; Rachel A Zuckerbrot; Peter S Jensen; Kareem Ghalib; Danielle Laraque; Ruth E K Stein
Journal:  Pediatrics       Date:  2007-11       Impact factor: 7.124

9.  Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.

Authors:  David Brent; Graham Emslie; Greg Clarke; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Marty Keller; Benedetto Vitiello; Louise Ritz; Satish Iyengar; Kaleab Abebe; Boris Birmaher; Neal Ryan; Betsy Kennard; Carroll Hughes; Lynn DeBar; James McCracken; Michael Strober; Robert Suddath; Anthony Spirito; Henrietta Leonard; Nadine Melhem; Giovanna Porta; Matthew Onorato; Jamie Zelazny
Journal:  JAMA       Date:  2008-02-27       Impact factor: 56.272

10.  Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs.

Authors:  Anne M Libby; David A Brent; Elaine H Morrato; Heather D Orton; Richard Allen; Robert J Valuck
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112

View more
  4 in total

Review 1.  Pharmacotherapy for Pediatric Generalized Anxiety Disorder: A Systematic Evaluation of Efficacy, Safety and Tolerability.

Authors:  Eric T Dobson; Jeffrey R Strawn
Journal:  Paediatr Drugs       Date:  2016-02       Impact factor: 3.022

2.  Long-Run Trends in Antidepressant Use Among Youths After the FDA Black Box Warning.

Authors:  Nilay Kafali; Ana Progovac; Sherry Shu-Yeu Hou; Benjamin Lê Cook
Journal:  Psychiatr Serv       Date:  2017-12-15       Impact factor: 3.084

3.  Autophagy Induction and Accumulation of Phosphorylated Tau in the Hippocampus and Prefrontal Cortex of Adult C57BL/6 Mice Subjected to Adolescent Fluoxetine Treatment.

Authors:  Jorge A Sierra-Fonseca; Minerva Rodriguez; Anapaula Themann; Omar Lira; Francisco J Flores-Ramirez; Javier Vargas-Medrano; Bharathi S Gadad; Sergio D Iñiguez
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 4.  Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified.

Authors:  Glen I Spielmans; Tess Spence-Sing; Peter Parry
Journal:  Front Psychiatry       Date:  2020-02-13       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.